Mr. More joined Domain as a Kauffman Fellow in 1996, and he became a Partner in 2000. Present board memberships include Esprit Pharma, Glaukos, Novalar Pharmaceuticals, NovaCardia, OmniSonics Medical Technologies, TargetRx and Windward Medical. Past board memberships include ESP Pharma (acquired by Protein Design Labs, Inc.), Proxima Therapeutics (acquired by Cytyc Corporation) and Onux Medical (acquired by C.R. Bard). Mr. More was also responsible for Domain's investment in IntraLase (NASDAQ:ILSE). Additionally, Mr. More serves as a founding board member for Kauffman Fellows Program and serves as an Advisory Board member for Montagu Newhall Associates, Fresh Tracks Capital, Okapi Ventures and the Medical Industry Group, NVCA. From 1997-1998, Mr. More served as the Chief Operating Officer of Small Molecule Therapeutics, a Domain portfolio company subsequently purchased by Morphochem AG. From 1992 to 1995, Mr. More was with Pharmacia Biotech in sales. Prior to joining Pharmacia, Mr. More held a research position at Somatogen, a company developing a recombinant blood substitute that was subsequently bought by Baxter. While attending business school, Mr. More worked with MedVest, an early-stage venture group in Washington, D.C.